198 related articles for article (PubMed ID: 9863870)
21. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.
Frankel FA; Marchand B; Turner D; Götte M; Wainberg MA
Antimicrob Agents Chemother; 2005 Jul; 49(7):2657-64. PubMed ID: 15980333
[TBL] [Abstract][Full Text] [Related]
22. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
23. Additional mutations detected in sequential HIV-1 isolates from ZDV-treated patients.
Magierowska-Jung M; Agut H; Katlama C; Autran B; Huraux JM
J Med Virol; 1997 Jan; 51(1):48-55. PubMed ID: 8986949
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
25. Antiretroviral resistance in viral isolates from HIV-1-transmitting mothers and their infants.
Bauer GR; Colgrove RC; Larussa PS; Pitt J; Welles SL
AIDS; 2006 Aug; 20(13):1707-12. PubMed ID: 16931934
[TBL] [Abstract][Full Text] [Related]
26. Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.
Olson SC; Ngo-Giang-Huong N; Beck I; Deng W; Britto P; Shapiro DE; Bumgarner RE; Mullins JI; Van Dyke RB; Jourdain G; Frenkel LM
AIDS; 2015 Jul; 29(12):1467-71. PubMed ID: 26244386
[TBL] [Abstract][Full Text] [Related]
27. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
de Ronde A; van Dooren M; van Der Hoek L; Bouwhuis D; de Rooij E; van Gemen B; de Boer R; Goudsmit J
J Virol; 2001 Jan; 75(2):595-602. PubMed ID: 11134272
[TBL] [Abstract][Full Text] [Related]
28. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
Novitsky V; Wester CW; DeGruttola V; Bussmann H; Gaseitsiwe S; Thomas A; Moyo S; Musonda R; Van Widenfelt E; Marlink RG; Essex M
AIDS Res Hum Retroviruses; 2007 Jul; 23(7):868-78. PubMed ID: 17678469
[TBL] [Abstract][Full Text] [Related]
29. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
[TBL] [Abstract][Full Text] [Related]
30. Quantitative differences in the distribution of zidovudine resistance mutations in multiple post-mortem tissues from AIDS patients.
Atkins M; Strappe P; Kaye S; Loveday C; McLaughlin JE; Johnson MA; Tedder RS; Griffiths PD; Emery VC
J Med Virol; 1998 Jun; 55(2):138-46. PubMed ID: 9598935
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP
AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278
[TBL] [Abstract][Full Text] [Related]
32. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.
Kuritzkes DR; Shugarts D; Bakhtiari M; Poticha D; Johnson J; Rubin M; Gingeras TR; Kennedy M; Eron JJ
J Acquir Immune Defic Syndr; 2000 Jan; 23(1):26-34. PubMed ID: 10708053
[TBL] [Abstract][Full Text] [Related]
33. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
34. Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility.
Bulgheroni E; Croce F; Citterio P; Viganò O; Visonà R; Sala E; Galli M; Rusconi S
J Clin Virol; 2004 Jan; 29(1):27-32. PubMed ID: 14675866
[TBL] [Abstract][Full Text] [Related]
35. Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
Bélec L; Legoff J; Si-Mohamed A; Andréoletti L; Mbopi-Kéou FX; Kolberg J; Matta M; Detmer J; Piketty C; Kazatchkine MD
J Med Virol; 2002 Sep; 68(1):1-6. PubMed ID: 12210423
[TBL] [Abstract][Full Text] [Related]
36. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay.
Wilson JW; Bean P; Robins T; Graziano F; Persing DH
J Clin Microbiol; 2000 Aug; 38(8):3022-8. PubMed ID: 10921971
[TBL] [Abstract][Full Text] [Related]
37. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
Hu Z; Giguel F; Hatano H; Reid P; Lu J; Kuritzkes DR
J Virol; 2006 Jul; 80(14):7020-7. PubMed ID: 16809307
[TBL] [Abstract][Full Text] [Related]
38. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
39. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
40. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences.
Yahi N; Tamalet C; Tourrès C; Tivoli N; Ariasi F; Volot F; Gastaut JA; Gallais H; Moreau J; Fantini J
J Clin Microbiol; 1999 Dec; 37(12):4099-106. PubMed ID: 10565938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
